Observational Study of Subjects Having Routine Recurrence Screening for Bladder Cancer
- Conditions
- Bladder Cancer Recurrence
- Registration Number
- NCT00903240
- Lead Sponsor
- Predictive Biosciences
- Brief Summary
The purpose of this study is to detect recurrent bladder cancer using a combination of protein and DNA biomarkers in urine
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1000
- Intact bladder
- Scheduled for cystoscopy for transitional cell bladder cancer recurrence screening
- Urine donated prior to cystoscopy, Bladder biopsy, chemotherapy, intravesical therapy, radiation or TUR
- Must be willing to sign IRB approved informed consent
- History or current diagnosis of any cancer except transitional cell bladder cancer or basal cell cancer
- Known diagnosis of any autoimmune disease or HIV, HCV or HBV
- History or current TB or any other active infection
- Subject has gross hematuria
- Receiving chemotherapy, intravesical therapy or radiation within 30 days of enrollment
- Any surgery except urologic within past 30 days
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (20)
BCG Oncology
🇺🇸Phoenix, Arizona, United States
Urology Associates
🇺🇸Engelwood, Colorado, United States
Atlantic Urological Associates
🇺🇸Daytona Beach, Florida, United States
Winter Park Urology
🇺🇸Orlando, Florida, United States
Metropolitan Urology
🇺🇸Jeffersonville, Indiana, United States
Mayo Validation Support Services
🇺🇸Rochester, Minnesota, United States
Metro Urology
🇺🇸Woodbury, Minnesota, United States
Associates in Urology/Urology Group of NJ
🇺🇸741 Northfield Avenue, New Jersey, United States
Coastal Urology Associates
🇺🇸Brick, New Jersey, United States
Capital Regional Urological Surgeons
🇺🇸Albany, New York, United States
Scroll for more (10 remaining)BCG Oncology🇺🇸Phoenix, Arizona, United States